 |
 |
MORRIS SCHAMBELAN, M.D., Professor of Medicine, Endocrinology
In metabolic studies carried out in the setting of the General Clinical Research Center (GCRC), Dr. Schambelan is investigating the pathogenesis of endocrinologic and metabolic perturbations in patients with HIV infection with a particular emphasis on the hyperlipdemia, insulin resistance and body composition abnormalities seen recently in the era of highly active antiretroviral therapy. Studies are also carried out in patients with related catabolic states (e.g. end-state renal failure, aging). Treatment options are evaluated both in intensive inpatient studies as well as in placebo-controlled outpatient clinical trials. Therapies under current evaluation include hormonal anabolic agents (recombinant human growth hormone, anabolic steroids), inhibitors of cytokine production (thalidomide), insulin-sensitizing agents and, in patients with end-stage renal disease, the effects of amelioration of acidosis and/or resistance exercise training. Outcomes are assessed using metabolic balance techniques (nitrogen and electrolyte balance); measures of body composition (dual energy x-ray absorptiometry, CT scanning, biological impedance analysis, isotope dilution); energy and substrate metabolism (indirect calorimeter, doubly-labeled water); carbohydrate, lipid and protein metabolism (stable isotopes, muscle biopsy); and muscle function (exercise physiology, magnetic resonance spectroscopy). Dr. Schambelan also has a long-standing interest in GCRC-based studies of inherited disorders of electrolyte transport and rare forms of secondary hypertension with a current focus on defining the molecular basis for such disorders.
SELECTED PUBLICATIONS:
|
|